14 DAY TRIAL // A particular agenda, dedicated to helping businesses, governments, and the consumers anticipate and manage the possible health and environmental implications of nanotechnology, will be held on Thursday, June 29th at 12:30 p.m. in the 6th floor board room of the Woodrow Wilson International Center for Scholars, Ronald Reagan Building and International Trade Center.
This program is part of the Wilson Center's Project on Emerging Nanotechnologies' "Perspectives" series designed to inform on the development, commercialization, and oversight of nanotechnology.
The most important guest is Dr. Barry Park, chief operating officer of Oxonica. Dr. Park formerly worked for Raychem Ltd., he is co-author of 20 scientific papers, and, in the same time, he is an inventor whose work has led to over 120 patents granted worldwide.
On the other hand, Oxonica is one of Europe's leading nanomaterials companies, which emerged from Oxford University in Great Britain in 1999. Its commercialized products include Envirox Fuel Borne Catalyst (used in diesel engines to reduce fuel consumption and particulate emissions) and Optisol UV Absorber (a photostable UV absorber that provides enhanced and longer lasting protection against UVA in suncare and anti-aging products).
In 2005, Boots Group plc, Britain's leader in pharmacy chains market segment, incorporated Optisol in their new Soltan Facial Sun Defense Cream, now sold widely in stores throughout the United Kingdom.
According to a recent study led by Lux Research, more than $32 billion in products incorporating nanotechnology were sold last year. More precisely, this sums up to about 300 nanotechnology consumer products, and an estimated 600 nanotechnology raw materials, intermediate components, and industrial equipment items used by manufacturers.
Webcast LIVE of the program at http://www.wilsoncenter.org/nano.